Literature DB >> 18159783

Gamma-hydroxybutyric acid (GHB) withdrawal: a case report.

W R Murray Bennett1, Lawrence G Wilson, Peter P Roy-Byrne.   

Abstract

GHB is an increasingly popular drug of abuse that can be associated in select cases with growing dependence and a severe withdrawal syndrome. While benzodiazepines are recommended for treatment of the withdrawal syndrome, some cases have been described as benzodiazepine-resistant. The authors describe treatment of such a case, which was unsuccessfully treated initially with benzodiazepines, then successfully treated with adjuvant atypical neuroleptics, and offer a possible neurochemical explanation for why such agents may be theoretically more effective than benzodiazepines in treating GHB withdrawal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18159783     DOI: 10.1080/02791072.2007.10400616

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  4 in total

Review 1.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

2.  Area-level socioeconomic status in relation to outcomes in gamma-hydroxybutyrate intoxication.

Authors:  Ilene B Anderson; Susan Y Kim-Katz; Jo Ellen Dyer; Gillian E Earnest; John P Lamb; Paul D Blanc
Journal:  Clin Toxicol (Phila)       Date:  2009-01       Impact factor: 4.467

Review 3.  GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome.

Authors:  Francesco P Busardò; Alan W Jones
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

Review 4.  Toxicological Characterization of GHB as a Performance-Enhancing Drug.

Authors:  Arianna Giorgetti; Francesco Paolo Busardò; Raffaele Giorgetti
Journal:  Front Psychiatry       Date:  2022-04-18       Impact factor: 5.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.